Lundbeck enters licensing agreement for antidepressant in India
Danish pharmaceutical firm Lundbeck has partnered up with Sun Pharmaceutical Industries in India.
by marketwire, translated by catherine brett
Lundbeck has entered into a licensing agreement with Sun Pharmaceutical Industries, giving the latter exclusive rights to sell antidepressant drug vortioxentine in India.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
The Lundbeck Foundation delivers record-breaking result
For subscribers
Lundbeck faces criticism over new share structure
For subscribers
